Please assess the completion status of the following clinical trial:

Trial Title: Persistent Pulmonary Hypertension of the Newborn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent by the parent(s) or the legal representative(s).~2. Term and near term newborns (gestational age \> 34 weeks).~3. Post natal age ≥ 12 hours and \< 7 days.~4. Weight at birth ≥ 2,000 g.~5. Idiopathic PPHN or PPHN due to parenchymal lung disease~6. Documented diagnosis of pulmonary hypertension (PH) confirmed by echocardiography.~7. Need for continued inhaled nitric oxide (iNO) at a dose \> 10ppm after at least 4 hours of continuous iNO treatment.~8. Two oxygenation index (OI) values ≥ 12 taken at least 30 minutes apart, in the 12 hours prior to randomization and while the patient is receiving iNO treatment.~9. Mechanical ventilation with fraction of inspired oxygen (FiO2) ≥ 50% at randomization.~Exclusion Criteria:~1. PH associated with conditions other than PPHN.~2. Immediate need for cardiac resuscitation or extracorporeal membrane oxygenation (ECMO).~3. Lethal congenital anomalies.~4. Congenital Diaphragmatic Hernia.~5. Significant structural cardiac anomalies.~6. Medically significant pneumothorax.~7. Active seizures.~8. Expected duration of mechanical ventilation of less than 48 hours.~9. Mean systemic blood pressure \< 35 mmHg despite therapy with volume infusions and cardiotonic support.~10. Hepatic failure or all conditions with alanine aminotransferase (ALT) values \> 2 x upper limit of normal (ULN).~11. Renal function impairment such as serum creatinine \> 3 x ULN or anuria.~12. Known intracranial hemorrhage grade III or IV.~13. Either hemoglobin or hematocrit level \< 75% of the lower limit of normal (LLN).~14. Thrombocytopenia (platelet count \< 50,000 cells /µL).~15. Leukopenia (WBC \< 2,500 cells/ µL).~16. Any condition precluding the use of a nasogastric/orogastric tube.~17. Administration of prohibited medication prior to randomization.

- Gender: ALL
- Minimum Age: 12 Hours
- Maximum Age: 7 Days
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bosentan
- 2 (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).